Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Xytronyx

This article was originally published in The Gray Sheet

Executive Summary

Xytronyx: Receives "approvable" letter from FDA for its PTM periodontal tissue monitor device. Final approval of the "chair-side" test for periodontitis remains contingent upon "certain manufacturing requirements and labeling issues," San Diego-based Xytronyx says. In September 1996, the firm submitted a revised premarket approval application for the device following an initial rejection by FDA in 1991 due to inadequate data ("The Gray Sheet" Nov. 18, 1991, In Brief). Formerly called the PerioGard, the device is sold in Europe by Hawe-Neos Dental. Xytronyx has signed a letter of intent with Steri-Oss for distribution of PTM in North America...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT008193

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel